Gelonghui, January 30, 丨 Xiangxue Pharmaceutical (300147.SZ) announced its 2023 annual performance forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 277.7 million yuan - 467.7 million yuan, loss of 533.16 million yuan for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of 213.8 million yuan - 403.8 million yuan, loss of 553.11 million yuan for the same period last year; operating income of 2242.7 million yuan - 2324.9 million yuan, after deduction of operating income of 219.7 million yuan - RMB 22.27 million 2.7 million yuan.
In 2023, focusing on development strategies and annual operating goals, the company made efforts to reduce the impact of the market environment on the company by optimizing internal management and vigorously expanding markets outside the province. Under the circumstances where the operating income of Atomic Energy Company Hubei Tianji Pharmaceutical Co., Ltd. was not included in the scope of the consolidated statement, the company's consolidated revenue remained stable. Among them, the revenue of the proprietary Chinese medicine section of the core business increased by more than 100%. At the same time, the company continuously improved its cost control capabilities and continued to promote various cost reduction and efficiency measures. Various expenses also declined, and net profit increased year-on-year. Due to factors such as high financial expenses, heavy asset burdens, and asset disposal losses, the company's overall net profit is still in a state of loss, but it has shown a gradual narrowing trend.